Camber Capital Management LP Biomarin Pharmaceutical Inc Transaction History

Camber Capital Management LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$74.43 - $92.22 $63.3 Million - $78.4 Million	850,000 Added 340.0%	1,100,000 $90.6 Million
Q1 2024 May 15, 2024	BUY	$83.81 - $99.0 $21 Million - $24.8 Million	250,000 New	250,000 $21.8 Million
Q3 2023 Nov 14, 2023	BUY	$85.07 - $94.48 $25.5 Million - $28.3 Million	300,000 New	300,000 $26.5 Million
Q3 2022 Nov 14, 2022	SELL	$82.16 - $96.94 $57.5 Million - $67.9 Million	-700,000 Reduced 46.67%	800,000 $67.8 Million
Q2 2022 Aug 15, 2022	BUY	$71.48 - $86.85 $14.3 Million - $17.4 Million	200,000 Added 15.38%	1,500,000 $124 Million
Q1 2022 May 16, 2022	BUY	$74.28 - $92.69 $21.2 Million - $26.4 Million	285,000 Added 28.08%	1,300,000 $100 Million
Q4 2021 Feb 14, 2022	SELL	$71.72 - $91.47 $9.68 Million - $12.3 Million	-135,000 Reduced 11.74%	1,015,000 $89.7 Million
Q3 2021 Nov 15, 2021	BUY	$74.77 - $85.47 $86 Million - $98.3 Million	1,150,000 New	1,150,000 $88.9 Million
Q4 2020 Feb 16, 2021	SELL	$72.61 - $90.2 $29 Million - $36.1 Million	-400,000 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$71.87 - $131.03 $28.7 Million - $52.4 Million	400,000 New	400,000 $30.4 Million

638

178M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Camber Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Camber Capital Management LP with notifications on news.